Please login to the form below

Perjeta

This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

The drug presents a new challenge to Roche’s dominant position in the HER2-positive breast cancer market, which includes a trio of targeted treatments – Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla ... The FDA approval and EMA

Latest news

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Final decision due by 18 October. A fixed-dose combination of Roche’s HER2 drugs Herceptin and Perjeta has started a review at the US Food and Drug Administration (FDA), with ... Perjeta has been growing strongly – rising a third to $2.8bn last year
Seattle Genetics wins FDA priority review for oral HER2 drug

Herceptin plus Xeloda is a standard treatment regimen for HER2-positive breast cancer, in patients previously treated with Herceptin and Roche’s other HER-2 targeting drugs Perjeta (pertuzumab) and Kadcyla
Roche posts minor sales miss in Q4 as biosimilar pressure grows

Schwan highlighted four of these newer Roche medicines as driving the sales growth, namely Perjeta (pertuzumab) for HER2-positive breast cancer, Ocrevus (ocrelizumab) for multiple sclerosis, haemophilia therapy Hemlibra (emicizumab) and
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine). ... This first regulatory approval is based on the DESTINY-Breast01 trial in patients who had previously been treated with Herceptin, Perjeta or Kadcyla.
EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

HER2 antibodies, lagging behind Herceptin and Perjeta (pertuzumab).

More from news
Approximately 21 fully matching, plus 55 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

It has entered into a market dominated by Herceptin and other HER2-targeted therapies such as Perjeta and Tykerb.
20 for 2020 – Five pharma companies to watch

treatment pathway in HER2-positive breast cancer as quickly as possible, challenging Roche’s duo of Herceptin and Perjeta (pertuzumab).
The Cystic Fibrosis Buyers’ Club

cancer drug Perjeta.
Back to the future

In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

Genentech’s Perjeta (pertuzumab). due to lack of sufficient evidence to demonstrate a clinically meaningful overall survival benefit in early-stage disease.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Leader: Exceptionally competitive salary

Healthcare Account Director: Competitive

Healthcare Lead Copywriter: Competitive

Healthcare Senior Account Manager: Competitive

Medical Editor: Competitive

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....